Shareholder Letter from CEO July 2023
July 31, 2023
Dear Imagion Biosystems Shareholders, It has been an incredible first month ramping up as Chief Executive Officer with Team Imagion Biosystems. With this quarter’s 4C
Press & Media Coverage
Catch up on our latest press coverage
Quarterly Activity Report and Appendix 4C for 30 June 2023
July 31, 2023
Highlights include: MagSense® HER2 Phase 1 Study achieves enrolment target Expands collaboration with Siemens Healthineers Dr. Isaac Bright appointed as CEO MELBOURNE – Imagion Biosystems (ASX:IBX),
Imagion expands collaboration with Siemens Healthineers to United States
June 28, 2023
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce it has
Imagion set to complete the MagSense® HER2 Phase 1 Study
June 21, 2023
Highlights Study achieves enrolment target Study to formally close to new enrolments on 31 July Study results support further clinical development as MRI imaging agent
Imagion Announces New CEO
June 19, 2023
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare through the early detection of cancer, is pleased to announce it has appointed Isaac
[White Paper] Molecular Imaging: Changing the Way We Look at Cancer
June 1, 2023
Australasian Biotechnology | Vol 33 Number 1 Imagion authored a white paper, published in the April issue of Australasian Biotechnology, discussing current medical imaging technologies,
Watch our latest media coverage
Recent Press Coverage
14:13
4:13
4:09
4:19
16:09
5:26
7:30
16:30
18:44
3:10
4:41
Transforming medical imaging for early disease detection
We’re on a mission to make cancer more detectable.